Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia

NACompletedINTERVENTIONAL
Enrollment

340

Participants

Timeline

Start Date

December 18, 2003

Primary Completion Date

July 5, 2018

Study Completion Date

July 20, 2018

Conditions
Acute Myeloid Leukemia
Interventions
PROCEDURE

Reduced Intensity Conditioning Stem Cell Transplantation

"One of the following conditioning regimens:~1. Busulphan (orally or IV), fludarabine~2. Fludarabine, carmustine, melfalan~3. Cyclophosphamide, fludarabine"

Trial Locations (25)

2050

Royal Prince Alfred Hospital, Camperdown

3002

Austalasian Leukaemia &Lymphoma Group Limited, East Melbourne

5000

Royal Adelaide Hospital, Adelaide

6021

Wellington Hospital, Wellington

20520

Turku University Hospital, Turku

26504

University Hospital of Patras, Pátrai

41345

Department of Hematology, Sahlgrenska University Hospital, Gothenburg

51014

Tartu University Hospital, Tartu

79106

Dept of Hematology, University Hospital, Freiburg im Breisgau

R3E 0V9

Cancer Care Manitoba, Winnipeg

L8N 3Z5

McMaster Site Ward 3Z, Hamilton Health Sciences, Hamilton

K1H 8L6

Hematology, Ottawa Hospital, Ottawa

H1T 2M4

Hématologie, Maisonneuve-Rosemont Hospital, Montreal

H3A 1A1

Hematology, Royal Victoria Hospital, Montreal

G1J 1Z4

Hématologie, Hospital CHA Enfant-Jésus, Québec

Unknown

L'Hôtel Dieu de Quebec, Québec

Christchurch Hospital, Christchurch

Sunderby Hospital, Luleå

Skåne University Hospital Lund, Lund

University Hospital Örebro, Örebro

Karolinska University Hospital Huddinge, Stockholm

Karolinska University Hospital Solna, Stockholm

Uppsala Akademiska Hospital, Uppsala

S7N 4H4

Saskatoon Cancer Centre, Saskatoon

0027

Section of Hematology, National Hospital, Oslo

All Listed Sponsors
collaborator

The Canadian Blood and Marrow Transplant Group

NETWORK

collaborator

Australasian Leukaemia and Lymphoma Group

OTHER

lead

Vastra Gotaland Region

OTHER_GOV

NCT00342316 - Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter